Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT8010 + BAT1006 in advanced or metastatic solid tumors
CTR20241120Phase 2Active
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- May 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of BAT8010 and BAT1006 in Nonhematologic neoplasms, breast cancer, gastric adenocarcinoma and 1 more (3 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Dose-limiting toxicity and Safety and tolerability. Started May 2024; status: active.
02
Drugs
BAT8010BAT1006
03
Conditions
Nonhematologic neoplasmsbreast cancergastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20241120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241120.